|
Search
Collections
Benchmarks
Upload document
Organization
Merus NV
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
11 posters
Poster
Phase I Dose Escalation Study of MCLA-145, a Bispecific Antibody Targeting CD137 and PD-L1 in Solid Tumors
Poster
MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that does not show signs of peripheral toxicity in preclinical models
Poster
MCLA-145 activity correlates with PD-L1 expression levels
Poster
Antibody Generation Unbiased Screening CD137×PD-L1 Biclonics® Library
Poster
MCLA-145 Increases T Cell Activation in Primary Immune Assays
Poster
Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab and vinorelbine in HER2-amplified metastatic breast cancer patients (MBC) who had progressed on anti-HER2 antibody drug conjugates (ADCs)
Poster
MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced gastric/esophageal adenocarcinoma (GEA)
Poster
Antibody Generation Unbiased Screening CD137×PD-L1 Biclonics® Library
Poster
Phase I Dose Escalation Study of MCLA-145, a Bispecific Antibody Targeting CD137 and PD-L1 in Solid Tumors
Poster
MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that does not show signs of peripheral toxicity in preclinical models
Poster
MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells